Clinical trials
T-cell Acute Lymphoblastic Leukemia clinical trials
Below are recruiting t-cell acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 126 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06756321RecruitingEarly Phase 1
CAR T-cell therapy for relapsed blood cancers
This study tests a new type of therapy called CAR T-cells for people with blood cancers that have returned or not responded to standard treatments. CAR T-cells are made from your own immune cells and are trained to find and kill cancer cells.
Nantong, JiangsuAges 18–70 - NCT07513129RecruitingPhase 1
New drug combination for relapsed T-cell blood cancer in teens and young adults
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Houston, TexasAges 12–30 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT07483476Recruiting
Cell-free DNA in children with new ALL
This study looks at a special blood test that measures cell-free DNA (tiny pieces of genetic material) in children with acute lymphoblastic leukemia (ALL). It aims to understand how this test might help monitor the disease, and it is for newly diagnosed children who haven't started treatment yet.
ParisAges Up to 18 years - NCT07471789RecruitingPhase 1/Phase 2
CART84 therapy for AML and T-ALL leukemia
This trial tests a new treatment called CART84 (GYA01) for patients with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to standard treatments. CART84 uses specially engineered immune cells to target and destroy leukemia cells that have a protein called CD84 on their surface.
Barcelona, BarcelonaAges 18 years+ - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75 - NCT06793241RecruitingEarly Phase 1
Donor CAR-T cells for B-cell leukemia
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
Hangzhou, ZhejiangAges 18 years+ - NCT07361029RecruitingPhase 1
CAR T cell therapy for adults with returning B-cell leukemia
This trial tests whether specially designed immune cells (CAR T cells) that target CD19 can help adults whose B-cell acute lymphoblastic leukemia has not responded to standard treatments or has returned. The cells are made from your own blood and given back to you after a short chemotherapy preparation.
Riyadh, Riyadh RegionAges 18–75 - NCT07328503RecruitingPhase 2
CD22 CAR T-cells to prevent relapse after CD19 CAR T-cell therapy
This trial tests if giving a second type of CAR T-cell therapy that targets CD22 can help keep B-cell acute lymphoblastic leukemia (ALL) in remission for people who are already in remission after CD19 CAR T-cell treatment. It aims to reduce the risk of the cancer coming back.
Bethesda, MarylandAges 3–65 - NCT07256210RecruitingPhase 2
Donor NK cells to prevent leukemia return after stem cell transplant
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
MoscowAges 1 month–25 years - NCT07246707RecruitingPhase 1
KSV01 injection for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
HangzhouAges 18–80 - NCT07227584RecruitingPhase 2
ALL treatment for adolescents and young adults
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
Boston, MassachusettsAges 18–51 - NCT07220993RecruitingPhase 1
Modified immune cells for aggressive T-cell cancers
This trial tests a new treatment using specially engineered immune cells (CAR T cells) from a past stem cell donor to attack cancer cells in people with certain types of T-cell cancers that have returned after a stem cell transplant. The goal is to see if this treatment can lead to remission so a second stem cell transplant can be done.
Houston, TexasAges Up to 75 years - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Duarte, CaliforniaAges 18 years+ - NCT07153068RecruitingPhase 1/Phase 2
SupCD7 CART therapy for CD7 positive blood cancers
This trial tests a special immune cell therapy (SupCD7 CART) that targets a protein called CD7 on cancer cells. It is for people with certain types of blood cancers (like T-ALL/LBL or AML) that have come back or not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT06686108RecruitingPhase 2
Medication combo to prevent lymphoma relapse after transplant
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
ShanghaiAges 14–55 - NCT07078929RecruitingPhase 1
CAR T-cell therapy for children with relapsed or refractory ALL
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
Bangkok, BangkoknoiAges 1–18 - NCT07070323RecruitingPhase 1/Phase 2
Nanobody CD5-CAR T cells for T-cell cancers
This trial tests a new treatment using your own or a donor's immune cells to fight certain T-cell cancers that haven't responded to standard therapies. It may help people who have few other options left.
Beijing, Beijing MunicipalityAges 1–70 - NCT07048535Recruiting
Long-term follow-up study for CAR T-cell therapy patients
This study follows children and young adults who received CAR T-cell therapy for B-cell ALL at least two years ago. It checks long-term side effects, how well the therapy worked over time, and quality of life, so doctors can better understand the lasting impacts of CAR T-cells.
Memphis, TennesseeAges Any age - NCT07039877RecruitingPhase 2
Low-dose venetoclax with itraconazole and TACL for relapsed or refractory ALL
This trial tests a combination of low-dose venetoclax (a targeted cancer pill) plus itraconazole (an antifungal) and chemotherapy drugs for adults with acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to first treatment.
Monterrey, Nuevo LeónAges 16–45 - NCT07012447RecruitingPhase 2
Venetoclax with azacytidine for newly diagnosed T-cell leukemia
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
Suzhou, JiangsuAges 14 years+ - NCT07003737Recruiting
Blinatumomab before stem cell transplant for high-risk B-ALL
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
Hangzhou, ZhejiangAges 18–65 - NCT06934382RecruitingPhase 1
CAR-T cell therapy for relapsed T-cell leukemia or lymphoma
This trial tests a new type of immunotherapy called anti-CD7 CAR-T cells for children and young adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to see if these specially engineered immune cells can find and destroy cancer cells that carry the CD7 protein.
Philadelphia, PennsylvaniaAges birth–29 years - NCT06918431RecruitingPhase 2
Erwinia asparaginase with chemo for new ALL or LBL
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
Phoenix, ArizonaAges 18–54
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for t-cell acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 126 recruiting t-cell acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t-cell acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- B-Cell Acute Lymphoblastic Leukemia, Adult
- B-Cell Lymphoblastic Leukemia
- B-Cell Lymphoblastic Leukemia/Lymphoma
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.